首页 > 最新文献

Medicines (Basel, Switzerland)最新文献

英文 中文
Contrast-Induced Encephalopathy in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. 慢性肾病和终末期肾病患者造影剂诱导的脑病:一项系统综述和荟萃分析
Pub Date : 2023-08-08 DOI: 10.3390/medicines10080046
Paul W Davis, Pajaree Krisanapan, Supawit Tangpanithandee, Charat Thongprayoon, Jing Miao, Mohamed Hassanein, Prakrati Acharya, Michael A Mao, Iasmina M Craici, Wisit Cheungpasitporn

Background: Contrast-induced encephalopathy (CIE) is an infrequent but serious neurological condition that occurs shortly after the administration of contrast during endovascular and angiography procedures. Patients suffering from chronic kidney disease (CKD) or end-stage kidney disease (ESKD) are considered to be at a higher risk of contrast medium neurotoxicity, due to the delayed elimination of the contrast medium. However, the occurrence and characteristics of CIE in CKD/ESKD patients have not been extensively investigated. Methods: We conducted a comprehensive literature search, utilizing databases such as MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, up to September 2022. The purpose was to identify documented cases of CIE among patients with CKD or ESKD. Employing a random-effects model, we calculated the pooled incidence and odds ratio (OR) of CIE in CKD/ESKD patients. Results: Our search yielded a total of eleven articles, comprising nine case reports and two observational studies. Among these studies, 2 CKD patients and 12 ESKD patients with CIE were identified. The majority of the CKD/ESKD patients with CIE (93%) had undergone intra-arterial contrast media and/or endovascular procedures to diagnose acute cerebrovascular disease, coronary artery disease, and peripheral artery disease. The male-to-female ratio was 64%, and the median age was 63 years (with an interquartile range of 55 to 68 years). In the two observational studies, the incidence of CIE was found to be 6.8% in CKD patients and 37.5% in ESKD patients, resulting in a pooled incidence of 16.4% (95% CI, 2.4%-60.7%) among the CKD/ESKD patients. Notably, CKD and ESKD were significantly associated with an increased risk of CIE, with ORs of 5.77 (95% CI, 1.37-24.3) and 223.5 (95% CI, 30.44-1641.01), respectively. The overall pooled OR for CIE in CKD/ESKD patients was 32.9 (95% CI, 0.89-1226.44). Although dialysis prior to contrast exposure did not prevent CIE, approximately 92% of CIE cases experienced recovery after undergoing dialysis following contrast exposure. However, the effectiveness of dialysis on CIE recovery remained uncertain, as there was no control group for comparison. Conclusions: In summary, our study indicates an association between CIE and CKD/ESKD. While patients with CIE showed signs of recovery after dialysis, further investigations are necessary, especially considering the lack of a control group, which made the effects of dialysis on CIE recovery uncertain.

背景:造影剂诱发的脑病(CIE)是一种少见但严重的神经系统疾病,在血管内和血管造影过程中施用造影剂后不久发生。患有慢性肾脏疾病(CKD)或终末期肾脏疾病(ESKD)的患者被认为具有较高的造影剂神经毒性风险,因为造影剂的消除延迟。然而,CIE在CKD/ESKD患者中的发生和特征尚未得到广泛的研究。方法:我们利用MEDLINE、EMBASE、Cochrane中央对照试验注册库和Cochrane系统评价数据库等数据库进行了全面的文献检索,检索时间截止到2022年9月。目的是确定CKD或ESKD患者中有记录的CIE病例。采用随机效应模型,我们计算了CKD/ESKD患者CIE的合并发生率和优势比(OR)。结果:我们共检索到11篇文章,包括9篇病例报告和2篇观察性研究。在这些研究中,确定了2例CKD患者和12例ESKD患者合并CIE。大多数CKD/ESKD合并CIE的患者(93%)接受了动脉内造影剂和/或血管内手术来诊断急性脑血管疾病、冠状动脉疾病和外周动脉疾病。男女比例为64%,中位年龄为63岁(四分位数范围为55至68岁)。在两项观察性研究中,CKD患者的CIE发生率为6.8%,ESKD患者的发生率为37.5%,CKD/ESKD患者的总发生率为16.4% (95% CI, 2.4%-60.7%)。值得注意的是,CKD和ESKD与CIE风险增加显著相关,or分别为5.77 (95% CI, 1.37-24.3)和223.5 (95% CI, 30.44-1641.01)。CKD/ESKD患者CIE的总合并OR为32.9 (95% CI, 0.89-1226.44)。虽然造影剂暴露前的透析不能预防CIE,但大约92%的CIE病例在造影剂暴露后进行透析后恢复。然而,透析对CIE恢复的有效性仍然不确定,因为没有对照组进行比较。结论:总之,我们的研究表明CIE与CKD/ESKD之间存在关联。虽然CIE患者在透析后有恢复的迹象,但需要进一步的调查,特别是考虑到缺乏对照组,这使得透析对CIE恢复的影响不确定。
{"title":"Contrast-Induced Encephalopathy in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.","authors":"Paul W Davis,&nbsp;Pajaree Krisanapan,&nbsp;Supawit Tangpanithandee,&nbsp;Charat Thongprayoon,&nbsp;Jing Miao,&nbsp;Mohamed Hassanein,&nbsp;Prakrati Acharya,&nbsp;Michael A Mao,&nbsp;Iasmina M Craici,&nbsp;Wisit Cheungpasitporn","doi":"10.3390/medicines10080046","DOIUrl":"https://doi.org/10.3390/medicines10080046","url":null,"abstract":"<p><p><b>Background:</b> Contrast-induced encephalopathy (CIE) is an infrequent but serious neurological condition that occurs shortly after the administration of contrast during endovascular and angiography procedures. Patients suffering from chronic kidney disease (CKD) or end-stage kidney disease (ESKD) are considered to be at a higher risk of contrast medium neurotoxicity, due to the delayed elimination of the contrast medium. However, the occurrence and characteristics of CIE in CKD/ESKD patients have not been extensively investigated. <b>Methods:</b> We conducted a comprehensive literature search, utilizing databases such as MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, up to September 2022. The purpose was to identify documented cases of CIE among patients with CKD or ESKD. Employing a random-effects model, we calculated the pooled incidence and odds ratio (OR) of CIE in CKD/ESKD patients. <b>Results:</b> Our search yielded a total of eleven articles, comprising nine case reports and two observational studies. Among these studies, 2 CKD patients and 12 ESKD patients with CIE were identified. The majority of the CKD/ESKD patients with CIE (93%) had undergone intra-arterial contrast media and/or endovascular procedures to diagnose acute cerebrovascular disease, coronary artery disease, and peripheral artery disease. The male-to-female ratio was 64%, and the median age was 63 years (with an interquartile range of 55 to 68 years). In the two observational studies, the incidence of CIE was found to be 6.8% in CKD patients and 37.5% in ESKD patients, resulting in a pooled incidence of 16.4% (95% CI, 2.4%-60.7%) among the CKD/ESKD patients. Notably, CKD and ESKD were significantly associated with an increased risk of CIE, with ORs of 5.77 (95% CI, 1.37-24.3) and 223.5 (95% CI, 30.44-1641.01), respectively. The overall pooled OR for CIE in CKD/ESKD patients was 32.9 (95% CI, 0.89-1226.44). Although dialysis prior to contrast exposure did not prevent CIE, approximately 92% of CIE cases experienced recovery after undergoing dialysis following contrast exposure. However, the effectiveness of dialysis on CIE recovery remained uncertain, as there was no control group for comparison. <b>Conclusions:</b> In summary, our study indicates an association between CIE and CKD/ESKD. While patients with CIE showed signs of recovery after dialysis, further investigations are necessary, especially considering the lack of a control group, which made the effects of dialysis on CIE recovery uncertain.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10459670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging the Gap between Basic Research and Clinical Practice: The Growing Role of Translational Neurorehabilitation. 弥合基础研究与临床实践之间的差距:转化神经康复的作用越来越大。
Pub Date : 2023-08-01 DOI: 10.3390/medicines10080045
Mirjam Bonanno, Rocco Salvatore Calabrò

Translational neuroscience is intended as a holistic approach in the field of brain disorders, starting from the basic research of cerebral morphology and with the function of implementing it into clinical practice. This concept can be applied to the rehabilitation field to promote promising results that positively influence the patient's quality of life. The last decades have seen great scientific and technological improvements in the field of neurorehabilitation. In this paper, we discuss the main issues related to translational neurorehabilitation, from basic research to current clinical practice, and we also suggest possible future scenarios.

转化神经科学是一门以脑形态学基础研究为起点,并将其应用于临床的综合性脑疾病研究。这一概念可以应用于康复领域,以促进有希望的结果,积极影响患者的生活质量。在过去的几十年里,神经康复领域取得了巨大的科技进步。在本文中,我们讨论了与转化神经康复相关的主要问题,从基础研究到目前的临床实践,我们也提出了可能的未来情景。
{"title":"Bridging the Gap between Basic Research and Clinical Practice: The Growing Role of Translational Neurorehabilitation.","authors":"Mirjam Bonanno,&nbsp;Rocco Salvatore Calabrò","doi":"10.3390/medicines10080045","DOIUrl":"https://doi.org/10.3390/medicines10080045","url":null,"abstract":"<p><p>Translational neuroscience is intended as a holistic approach in the field of brain disorders, starting from the basic research of cerebral morphology and with the function of implementing it into clinical practice. This concept can be applied to the rehabilitation field to promote promising results that positively influence the patient's quality of life. The last decades have seen great scientific and technological improvements in the field of neurorehabilitation. In this paper, we discuss the main issues related to translational neurorehabilitation, from basic research to current clinical practice, and we also suggest possible future scenarios.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10101865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intermittent Proton Pump Inhibitor Therapy in Low-Risk Non-Variceal Upper Gastrointestinal Bleeding May Be Significantly Cost-Saving. 间歇质子泵抑制剂治疗低风险非静脉曲张上消化道出血可能显著节省成本。
Pub Date : 2023-07-20 DOI: 10.3390/medicines10070044
Yang Lei, Jennifer Halasz, Kerri L Novak, Stephen E Congly

Background: High-dose proton pump inhibitor (PPI) therapy, given either intermittently or continuously for non-variceal upper gastrointestinal bleeding (NV-UGIB), is efficacious. Using intermittent PPI for low-risk patients may be cost-saving. Our objective was to estimate the annual cost savings if all low-risk NV-UGIB patients received intermittent PPI therapy.

Methods: Patients who presented to hospital in Calgary, Alberta, who received a PPI for NV-UGIB from July 2015 to March 2017 were identified using ICD-10 codes. Patients were stratified into no endoscopy, high-risk, and low-risk lesion groups and further subdivided into no PPI, oral PPI, intermittent intravenous (IV), and continuous IV subgroups. Average length of stay (LOS) in each subgroup and costs were calculated.

Results: We identified 4141 patients with NV-UGIBs, (median age 61, 57.4% male). One-thousand two-hundred and thirty-one low-risk patients received continuous IV PPI, with an average LOS of 6.8 days (95% CI 6.2-7.3) versus 4.9 days (95% CI 3.9-5.9) for intermittent IV patients. If continuous IV PPI patients instead received intermittent IV PPI, 3852 patient days and CAD 11,714,390 (2017 CAD)/year could be saved.

Conclusions: Using real-world administrative data, we demonstrate that a sizable portion of low-risk patients with NV-UGIB who were given continuous IV PPI if switched to intermittent IV therapy could generate significant potential cost savings.

背景:间歇或连续给予大剂量质子泵抑制剂(PPI)治疗非静脉曲张性上消化道出血(NV-UGIB)是有效的。对低风险患者使用间歇性PPI可能节省成本。我们的目的是估计如果所有低风险NV-UGIB患者接受间歇性PPI治疗,每年节省的费用。方法:使用ICD-10代码对2015年7月至2017年3月在阿尔伯塔省卡尔加里医院接受过NV-UGIB PPI治疗的患者进行识别。将患者分为无内镜检查组、高危组和低危组,并进一步细分为无PPI组、口服PPI组、间歇静脉注射组和持续静脉注射组。计算每个亚组的平均住院时间(LOS)和费用。结果:我们确定了4141例NV-UGIBs患者,(中位年龄61岁,男性57.4%)。1231名低危患者接受持续静脉注射PPI,平均生存期为6.8天(95% CI 6.2-7.3),而间歇静脉注射患者为4.9天(95% CI 3.9-5.9)。如果将持续静脉注射PPI的患者改为间歇性静脉注射PPI,可节省3852个患者日和11,714,390加元(2017加元)/年。结论:使用现实世界的管理数据,我们证明了相当一部分低风险的NV-UGIB患者,如果将持续静脉注射PPI改为间歇性静脉注射治疗,可以产生显着的潜在成本节约。
{"title":"Intermittent Proton Pump Inhibitor Therapy in Low-Risk Non-Variceal Upper Gastrointestinal Bleeding May Be Significantly Cost-Saving.","authors":"Yang Lei,&nbsp;Jennifer Halasz,&nbsp;Kerri L Novak,&nbsp;Stephen E Congly","doi":"10.3390/medicines10070044","DOIUrl":"https://doi.org/10.3390/medicines10070044","url":null,"abstract":"<p><strong>Background: </strong>High-dose proton pump inhibitor (PPI) therapy, given either intermittently or continuously for non-variceal upper gastrointestinal bleeding (NV-UGIB), is efficacious. Using intermittent PPI for low-risk patients may be cost-saving. Our objective was to estimate the annual cost savings if all low-risk NV-UGIB patients received intermittent PPI therapy.</p><p><strong>Methods: </strong>Patients who presented to hospital in Calgary, Alberta, who received a PPI for NV-UGIB from July 2015 to March 2017 were identified using ICD-10 codes. Patients were stratified into no endoscopy, high-risk, and low-risk lesion groups and further subdivided into no PPI, oral PPI, intermittent intravenous (IV), and continuous IV subgroups. Average length of stay (LOS) in each subgroup and costs were calculated.</p><p><strong>Results: </strong>We identified 4141 patients with NV-UGIBs, (median age 61, 57.4% male). One-thousand two-hundred and thirty-one low-risk patients received continuous IV PPI, with an average LOS of 6.8 days (95% CI 6.2-7.3) versus 4.9 days (95% CI 3.9-5.9) for intermittent IV patients. If continuous IV PPI patients instead received intermittent IV PPI, 3852 patient days and CAD 11,714,390 (2017 CAD)/year could be saved.</p><p><strong>Conclusions: </strong>Using real-world administrative data, we demonstrate that a sizable portion of low-risk patients with NV-UGIB who were given continuous IV PPI if switched to intermittent IV therapy could generate significant potential cost savings.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparative Study of Tumor-Specificity and Neurotoxicity between 3-Styrylchromones and Anti-Cancer Drugs. 3-苯乙烯基色素与抗癌药物肿瘤特异性及神经毒性的比较研究。
Pub Date : 2023-07-14 DOI: 10.3390/medicines10070043
Tomoyuki Abe, Hiroshi Sakagami, Shigeru Amano, Shin Uota, Kenjiro Bandow, Yoshihiro Uesawa, Shiori U, Hiroki Shibata, Yuri Takemura, Yu Kimura, Koichi Takao, Yoshiaki Sugita, Akira Sato, Sei-Ichi Tanuma, Hiroshi Takeshima

Background. Many anti-cancer drugs used in clinical practice cause adverse events such as oral mucositis, neurotoxicity, and extravascular leakage. We have reported that two 3-styrylchromone derivatives, 7-methoxy-3-[(1E)-2-phenylethenyl]-4H-1-benzopyran-4-one (Compound A) and 3-[(1E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-4H-1-benzopyran-4-one (Compound B), showed the highest tumor-specificity against human oral squamous cell carcinoma (OSCC) cell lines among 291 related compounds. After confirming their superiority by comparing their tumor specificity with newly synthesized 65 derivatives, we investigated the neurotoxicity of these compounds in comparison with four popular anti-cancer drugs. Methods: Tumor-specificity (TSM, TSE, TSN) was evaluated as the ratio of mean CC50 for human normal oral mesenchymal (gingival fibroblast, pulp cell), oral epithelial cells (gingival epithelial progenitor), and neuronal cells (PC-12, SH-SY5Y, LY-PPB6, differentiated PC-12) to OSCC cells (Ca9-22, HSC-2), respectively. Results: Compounds A and B showed one order of magnitude higher TSM than newly synthesized derivatives, confirming its prominent tumor-specificity. Docetaxel showed one order of magnitude higher TSM, but two orders of magnitude lower TSE than Compounds A and B. Compounds A and B showed higher TSM, TSE, and TSN values than doxorubicin, 5-FU, and cisplatin, damaging OSCC cells at concentrations that do not affect the viability of normal epithelial and neuronal cells. QSAR prediction based on the Tox21 database suggested that Compounds A and B may inhibit the signaling pathway of estrogen-related receptors.

背景。临床上使用的许多抗癌药物会引起口腔黏膜炎、神经毒性和血管外渗漏等不良反应。我们报道了两个3-苯乙烯基色素衍生物,7-甲氧基-3-[(1E)-2-苯基乙烯基]- 4h -1-苯并吡喃-4- 1(化合物A)和3-[(1E)-2-(4-羟基苯基)乙烯基]-7-甲氧基- 4h -1-苯并吡喃-4- 1(化合物B),在291种相关化合物中对人口腔鳞状细胞癌(OSCC)细胞系表现出最高的肿瘤特异性。通过与新合成的65种衍生物的肿瘤特异性比较,证实了它们的优越性,我们研究了这些化合物与四种常用抗癌药物的神经毒性。方法:分别以人正常口腔间质细胞(牙龈成纤维细胞、牙髓细胞)、口腔上皮细胞(牙龈上皮祖细胞)和神经元细胞(PC-12、SH-SY5Y、LY-PPB6、分化PC-12)与OSCC细胞(Ca9-22、HSC-2)的平均CC50比值评估肿瘤特异性(TSM、TSE、TSN)。结果:化合物A和B的TSM比新合成的衍生物高1个数量级,证实了其肿瘤特异性。多西他赛的TSM值比化合物A和B高一个数量级,但TSE值比化合物A和B低两个数量级。化合物A和B的TSM、TSE和TSN值比阿霉素、5-FU和顺铂高,在不影响正常上皮细胞和神经元细胞活力的浓度下损害OSCC细胞。基于Tox21数据库的QSAR预测表明,化合物A和B可能抑制雌激素相关受体的信号通路。
{"title":"A Comparative Study of Tumor-Specificity and Neurotoxicity between 3-Styrylchromones and Anti-Cancer Drugs.","authors":"Tomoyuki Abe,&nbsp;Hiroshi Sakagami,&nbsp;Shigeru Amano,&nbsp;Shin Uota,&nbsp;Kenjiro Bandow,&nbsp;Yoshihiro Uesawa,&nbsp;Shiori U,&nbsp;Hiroki Shibata,&nbsp;Yuri Takemura,&nbsp;Yu Kimura,&nbsp;Koichi Takao,&nbsp;Yoshiaki Sugita,&nbsp;Akira Sato,&nbsp;Sei-Ichi Tanuma,&nbsp;Hiroshi Takeshima","doi":"10.3390/medicines10070043","DOIUrl":"https://doi.org/10.3390/medicines10070043","url":null,"abstract":"<p><p><b>Background.</b> Many anti-cancer drugs used in clinical practice cause adverse events such as oral mucositis, neurotoxicity, and extravascular leakage. We have reported that two 3-styrylchromone derivatives, 7-methoxy-3-[(1<i>E</i>)-2-phenylethenyl]-4<i>H</i>-1-benzopyran-4-one (Compound <b>A</b>) and 3-[(1<i>E</i>)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-4<i>H</i>-1-benzopyran-4-one (Compound <b>B</b>), showed the highest tumor-specificity against human oral squamous cell carcinoma (OSCC) cell lines among 291 related compounds. After confirming their superiority by comparing their tumor specificity with newly synthesized 65 derivatives, we investigated the neurotoxicity of these compounds in comparison with four popular anti-cancer drugs. <b>Methods:</b> Tumor-specificity (TS<sub>M</sub>, TS<sub>E</sub>, TS<sub>N</sub>) was evaluated as the ratio of mean CC<sub>50</sub> for human normal oral mesenchymal (gingival fibroblast, pulp cell), oral epithelial cells (gingival epithelial progenitor), and neuronal cells (PC-12, SH-SY5Y, LY-PPB6, differentiated PC-12) to OSCC cells (Ca9-22, HSC-2), respectively. <b>Results:</b> Compounds <b>A</b> and <b>B</b> showed one order of magnitude higher TS<sub>M</sub> than newly synthesized derivatives, confirming its prominent tumor-specificity. Docetaxel showed one order of magnitude higher TS<sub>M</sub>, but two orders of magnitude lower TS<sub>E</sub> than Compounds <b>A</b> and <b>B</b>. Compounds <b>A</b> and <b>B</b> showed higher TS<sub>M</sub>, TS<sub>E,</sub> and TS<sub>N</sub> values than doxorubicin, 5-FU, and cisplatin, damaging OSCC cells at concentrations that do not affect the viability of normal epithelial and neuronal cells. QSAR prediction based on the Tox21 database suggested that Compounds <b>A</b> and <b>B</b> may inhibit the signaling pathway of estrogen-related receptors.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9894476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Longitudinal Changes in Motor Estimation Error and Motor Function in Patients with Parkinson's Disease: A Case Report. 帕金森病患者运动估计误差和运动功能的纵向变化:一例报告。
Pub Date : 2023-07-06 DOI: 10.3390/medicines10070042
Katsuya Sakai, Tsubasa Kawasaki, Hiroya Kiminarita, Yumi Ikeda

Background and objectives: This report described two cases with clear longitudinal changes in motor estimation error (difference between the motor imagery and motor execution) and their progression and motor and activities of daily living (ADL) function changes in patients with PD.

Materials and methods: Patient 1 was a 68-year-old man (Hoehn and Yahr [H and Y] stage: IV, diagnosed with PD for 11.8 years) and patient 2 was a 68-year-old woman (H and Y stage: II, diagnosed with PD for 9.6 years). Imagined two-step test (iTST), two-step test (TST), and PD-related assessments (Unified Parkinson's Disease Rating Scale [UPDRS], and Freezing of Gait Questionnaire [FOGQ]) were assessed at baseline and after 6 months. Motor estimation error was calculated as the iTST distance minus TST distance.

Results: In patient 1, motor estimation error was greater after 6 months (baseline: 5.7 [4.8%]/after 6 months: 25.7 cm [26.1%]). Moreover, UPDRS and FOGQ total scores deteriorated after 6 months (UPDRS total: 29/34 point, and FOGQ: 9/16 point). Conversely, in patient 2, motor estimation error did not change notably (-3.6 [7.6%]/-2.5 cm [7.0%]), while UPDRS and FOGQ total scores improved after 6 months (UPDRS total: 17/12 point, and FOGQ: 6/1 point).

Conclusions: This report indicated that greater motor estimation error may be associated with declining motor and ADL function and disease progression in patients with PD.

背景与目的:本报告描述了两例PD患者在运动估计误差(运动想象与运动执行的差异)及其进展以及运动和日常生活活动(ADL)功能变化方面具有明显的纵向变化的病例。材料与方法:患者1为68岁男性(Hoehn and Yahr [H and Y]分期:IV期,诊断PD 11.8年),患者2为68岁女性(H和Y分期:II期,诊断PD 9.6年)。在基线和6个月后对想象两步测试(iTST)、两步测试(TST)和pd相关评估(统一帕金森病评定量表[UPDRS]和步态冻结问卷[FOGQ])进行评估。电机估计误差计算为iTST距离减去TST距离。结果:在患者1中,6个月后运动估计误差更大(基线:5.7[4.8%]/ 6个月后:25.7 cm[26.1%])。6个月后,UPDRS和FOGQ总分下降(UPDRS总分为29/34分,FOGQ总分为9/16分)。相反,在患者2中,运动估计误差没有明显变化(-3.6 [7.6%]/-2.5 cm[7.0%]),而UPDRS和FOGQ总分在6个月后有所改善(UPDRS总分:17/12分,FOGQ总分:6/1分)。结论:本报告表明,较大的运动估计误差可能与PD患者运动和ADL功能下降和疾病进展有关。
{"title":"Longitudinal Changes in Motor Estimation Error and Motor Function in Patients with Parkinson's Disease: A Case Report.","authors":"Katsuya Sakai,&nbsp;Tsubasa Kawasaki,&nbsp;Hiroya Kiminarita,&nbsp;Yumi Ikeda","doi":"10.3390/medicines10070042","DOIUrl":"https://doi.org/10.3390/medicines10070042","url":null,"abstract":"<p><strong>Background and objectives: </strong>This report described two cases with clear longitudinal changes in motor estimation error (difference between the motor imagery and motor execution) and their progression and motor and activities of daily living (ADL) function changes in patients with PD.</p><p><strong>Materials and methods: </strong>Patient 1 was a 68-year-old man (Hoehn and Yahr [H and Y] stage: IV, diagnosed with PD for 11.8 years) and patient 2 was a 68-year-old woman (H and Y stage: II, diagnosed with PD for 9.6 years). Imagined two-step test (iTST), two-step test (TST), and PD-related assessments (Unified Parkinson's Disease Rating Scale [UPDRS], and Freezing of Gait Questionnaire [FOGQ]) were assessed at baseline and after 6 months. Motor estimation error was calculated as the iTST distance minus TST distance.</p><p><strong>Results: </strong>In patient 1, motor estimation error was greater after 6 months (baseline: 5.7 [4.8%]/after 6 months: 25.7 cm [26.1%]). Moreover, UPDRS and FOGQ total scores deteriorated after 6 months (UPDRS total: 29/34 point, and FOGQ: 9/16 point). Conversely, in patient 2, motor estimation error did not change notably (-3.6 [7.6%]/-2.5 cm [7.0%]), while UPDRS and FOGQ total scores improved after 6 months (UPDRS total: 17/12 point, and FOGQ: 6/1 point).</p><p><strong>Conclusions: </strong>This report indicated that greater motor estimation error may be associated with declining motor and ADL function and disease progression in patients with PD.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin D Levels in Patients with Active and Remission Graves' Disease. 活动性和缓解性Graves病患者的维生素D水平
Pub Date : 2023-07-06 DOI: 10.3390/medicines10070041
Natapon Rattanamusik, Suriyon Uitrakul, Atchara Charoenpiriya

Background: The association between Graves' disease (GD) and serum vitamin D levels has been studied for decades although the results were controversial. Moreover, the difference in vitamin D levels between the different stages of GD is not well studied. Therefore, this study aimed to compare the vitamin D levels between active and remission GD and to investigate the factors affecting vitamin D levels in GD patients.

Methods: This cross-sectional study was performed between 1 January to 31 December 2021. The eligible patients were in either the active or remission stage of GD. The demographic and clinical data of the patients willing to participate in the study were collected, as well as their vitamin D levels. Comparisons of continuous parameters between the active and remission groups were performed using the Mann-Whitney U test, while categorical parameters were performed using the Chi-square test.

Results: 75 patients were diagnosed with GD, with 54.7% in the active stage. The mean vitamin D level was lower in the active GD group than in the remission GD group (28.23 vs. 31.58 ng/mL, respectively, p-value 0.079). The prevalence of vitamin D deficiency (i.e., serum vitamin D level < 20 ng/mL) in the active GD group was 14.6%, and in the remission GD group was 0% (p-value 0.02). Moreover, there was a significant negative correlation between the serum vitamin D level and serum free T4 level (p-value 0.03).

Conclusions: In spite of non-significance, patients with active GD had lower mean vitamin D levels compared to those with remission GD. The prevalence of vitamin D deficiency was significantly higher in the active GD patients. Additionally, a negative correlation between serum vitamin D levels and serum free T4 levels was observed in this study.

背景:格雷夫斯病(GD)与血清维生素D水平之间的关系已经研究了几十年,尽管结果存在争议。此外,维生素D水平在GD不同阶段的差异还没有得到很好的研究。因此,本研究旨在比较活动期和缓解期GD患者的维生素D水平,并探讨影响GD患者维生素D水平的因素。方法:本横断面研究于2021年1月1日至12月31日进行。符合条件的患者处于GD的活跃期或缓解期。研究人员收集了愿意参与研究的患者的人口学和临床数据,以及他们的维生素D水平。活动组和缓解组之间的连续参数比较使用Mann-Whitney U检验,而分类参数使用卡方检验。结果:确诊GD 75例,其中活动期患者占54.7%。活跃GD组的平均维生素D水平低于缓解GD组(分别为28.23和31.58 ng/mL, p值为0.079)。活跃GD组维生素D缺乏症(即血清维生素D水平< 20 ng/mL)的发生率为14.6%,缓解GD组为0% (p值为0.02)。血清维生素D水平与血清游离T4水平呈显著负相关(p值为0.03)。结论:尽管无显著性差异,但活动期GD患者的平均维生素D水平低于缓解期GD患者。活动期GD患者的维生素D缺乏症发生率明显较高。此外,本研究还发现血清维生素D水平与血清游离T4水平呈负相关。
{"title":"Vitamin D Levels in Patients with Active and Remission Graves' Disease.","authors":"Natapon Rattanamusik,&nbsp;Suriyon Uitrakul,&nbsp;Atchara Charoenpiriya","doi":"10.3390/medicines10070041","DOIUrl":"https://doi.org/10.3390/medicines10070041","url":null,"abstract":"<p><strong>Background: </strong>The association between Graves' disease (GD) and serum vitamin D levels has been studied for decades although the results were controversial. Moreover, the difference in vitamin D levels between the different stages of GD is not well studied. Therefore, this study aimed to compare the vitamin D levels between active and remission GD and to investigate the factors affecting vitamin D levels in GD patients.</p><p><strong>Methods: </strong>This cross-sectional study was performed between 1 January to 31 December 2021. The eligible patients were in either the active or remission stage of GD. The demographic and clinical data of the patients willing to participate in the study were collected, as well as their vitamin D levels. Comparisons of continuous parameters between the active and remission groups were performed using the Mann-Whitney U test, while categorical parameters were performed using the Chi-square test.</p><p><strong>Results: </strong>75 patients were diagnosed with GD, with 54.7% in the active stage. The mean vitamin D level was lower in the active GD group than in the remission GD group (28.23 vs. 31.58 ng/mL, respectively, <i>p</i>-value 0.079). The prevalence of vitamin D deficiency (i.e., serum vitamin D level < 20 ng/mL) in the active GD group was 14.6%, and in the remission GD group was 0% (<i>p</i>-value 0.02). Moreover, there was a significant negative correlation between the serum vitamin D level and serum free T4 level (<i>p</i>-value 0.03).</p><p><strong>Conclusions: </strong>In spite of non-significance, patients with active GD had lower mean vitamin D levels compared to those with remission GD. The prevalence of vitamin D deficiency was significantly higher in the active GD patients. Additionally, a negative correlation between serum vitamin D levels and serum free T4 levels was observed in this study.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9884450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multichannel Recovery Potential with Activated Autologous Intraovarian Platelet-Rich Plasma and Its Derivatives. 活化的自体卵巢内富血小板血浆及其衍生物的多通道恢复潜力。
Pub Date : 2023-07-03 DOI: 10.3390/medicines10070040
E Scott Sills, Samuel H Wood

Platelet-rich plasma (PRP) is an 'orthobiologic' with recognized roles in plastic surgery, musculoskeletal disorders, dentistry, dermatology, and more recently, 'ovarian rejuvenation'. Intraovarian PRP involves a complex secretome discharged after platelet activation, comprising multiple cytokine mediators delivered surgically to older or inactive ovarian tissue. Loss of oocyte meiotic fidelity and impaired fertilization accompanying advanced maternal age are already managed by IVF, but only with eggs provided by younger donors. However, if the observed effect of rectifying embryo ploidy error can be proven beyond case reports and small series, activated PRP (or its condensed plasma cytokines) would deliver a welcome therapeutic disruption that is difficult to overstate. Because shortcomings in ovarian function are presently addressed mainly by pharmacological approaches (i.e., via recombinant gonadotropins, GnRH analogs, or luteal support), autologous PRP would represent an unusual departure from these interventions. Given the diversity of platelet cargo proteins, the target response of intraovarian PRP is probably not confined to oocytes or follicles. For example, PRP manipulates signal networks driving improved perfusion, HOX regulation, N-glycan post-translational modification, adjustment of voltage-gated ion channels, telomere stabilization, optimization of SIRT3, and ribosome and mitochondria recovery in older oocytes. While multichannel signals operating on various pathways are not unique to reproductive biology, in intraovarian PRP this feature has received little study and may help explain why its standardization has been difficult. Against this background, our report examines the research themes considered most likely to shape clinical practice.

富血小板血浆(PRP)是一种“整形生物学”,在整形外科、肌肉骨骼疾病、牙科、皮肤病学以及最近的“卵巢年轻化”中发挥着公认的作用。卵巢内PRP涉及血小板激活后释放的复杂分泌组,包括多种细胞因子介质,通过手术输送到较老或无活性的卵巢组织。卵子减数分裂保真度的丧失和伴随高龄产妇的受精受损已经可以通过体外受精来解决,但只能使用年轻捐赠者提供的卵子。然而,如果观察到的纠正胚胎倍性错误的效果可以在病例报告和小系列之外得到证明,激活的PRP(或其凝聚的血浆细胞因子)将带来令人欢迎的治疗中断,这是很难夸大的。由于卵巢功能的缺陷目前主要通过药理学方法解决(即通过重组促性腺激素,GnRH类似物或黄体支持),自体PRP将代表着这些干预措施的不同寻常的偏离。鉴于血小板载货蛋白的多样性,卵巢内PRP的靶反应可能并不局限于卵母细胞或卵泡。例如,PRP操纵信号网络,驱动灌注改善、HOX调节、n -聚糖翻译后修饰、电压门控离子通道调节、端粒稳定、SIRT3优化以及老年卵母细胞的核糖体和线粒体恢复。虽然多通道信号在各种途径上运作并不是生殖生物学所独有的,但在卵巢内PRP中,这一特征几乎没有得到研究,这可能有助于解释为什么其标准化一直很困难。在此背景下,我们的报告考察了被认为最有可能塑造临床实践的研究主题。
{"title":"Multichannel Recovery Potential with Activated Autologous Intraovarian Platelet-Rich Plasma and Its Derivatives.","authors":"E Scott Sills,&nbsp;Samuel H Wood","doi":"10.3390/medicines10070040","DOIUrl":"https://doi.org/10.3390/medicines10070040","url":null,"abstract":"<p><p>Platelet-rich plasma (PRP) is an 'orthobiologic' with recognized roles in plastic surgery, musculoskeletal disorders, dentistry, dermatology, and more recently, 'ovarian rejuvenation'. Intraovarian PRP involves a complex secretome discharged after platelet activation, comprising multiple cytokine mediators delivered surgically to older or inactive ovarian tissue. Loss of oocyte meiotic fidelity and impaired fertilization accompanying advanced maternal age are already managed by IVF, but only with eggs provided by younger donors. However, if the observed effect of rectifying embryo ploidy error can be proven beyond case reports and small series, activated PRP (or its condensed plasma cytokines) would deliver a welcome therapeutic disruption that is difficult to overstate. Because shortcomings in ovarian function are presently addressed mainly by pharmacological approaches (i.e., via recombinant gonadotropins, GnRH analogs, or luteal support), autologous PRP would represent an unusual departure from these interventions. Given the diversity of platelet cargo proteins, the target response of intraovarian PRP is probably not confined to oocytes or follicles. For example, PRP manipulates signal networks driving improved perfusion, HOX regulation, N-glycan post-translational modification, adjustment of voltage-gated ion channels, telomere stabilization, optimization of SIRT3, and ribosome and mitochondria recovery in older oocytes. While multichannel signals operating on various pathways are not unique to reproductive biology, in intraovarian PRP this feature has received little study and may help explain why its standardization has been difficult. Against this background, our report examines the research themes considered most likely to shape clinical practice.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9894475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial Prescribing Preparedness of Croatian Medical Students-Did It Change between 2015 and 2019? 克罗地亚医科学生抗微生物药物处方准备情况——2015年至2019年有变化吗?
Pub Date : 2023-06-29 DOI: 10.3390/medicines10070039
Dora Palčevski, Andrej Belančić, Ivan Mikuličić, Eduard Oštarijaš, Robert Likić, Oliver Dyar, Vera Vlahović-Palčevski

Background: Antimicrobials are some of the most prescribed drugs by junior doctors, but studies suggest most medical graduates feel unprepared for their future prescribing tasks. The aim of the present study was to compare the self-reported preparedness to prudently prescribe antimicrobials of final-year medical students in Croatia in 2015 and 2019.

Methods: The same self-reported web-based survey on the preparedness to prescribe antibiotics was used in both 2015 and 2019. All final-year students at all four medical schools in Croatia (Osijek, Rijeka, Split, and Zagreb) were invited to participate in both 2015 and 2019. Preparedness scores were divided into "topic preparedness scores" and "global preparedness scores". Topic preparedness scores represented the percentage of students at a medical school who felt sufficiently prepared for each topic. They were first established at a medical school level and then at the national level. Global preparedness scores were determined for each student separately and then calculated at the medical school and national levels.

Results: The country's global preparedness score, representing the average proportion of topics in which students felt sufficiently prepared, was slightly higher in 2015 compared with the 2019 results (62.7% vs. 56.5%; p = 0.191). Croatian students reported higher preparedness in 2015 than in 2019 for 25 out of 27 topics included in the survey. The majority of students reported a need for more education on antibiotic use both in 2015 and 2019 (78.0% vs. 83.0%; p = 0.199).

Conclusions: Despite increasing antimicrobial stewardship activities in various healthcare settings, medical students who are about to start prescribing antibiotics on their own do not feel sufficiently prepared to do so. Antimicrobial stewardship programs should be designed to incorporate undergraduate medical student education, for instance, as a specific, mandatory course or integrated into other courses, such as clinical pharmacology.

背景:抗微生物药物是初级医生开得最多的药物之一,但研究表明,大多数医学毕业生对未来的处方任务感到措手不及。本研究的目的是比较2015年和2019年克罗地亚最后一年医科学生自我报告的谨慎开抗菌剂的准备情况。方法:2015年和2019年采用相同的基于网络的自我报告抗生素处方准备调查。克罗地亚所有四所医学院(奥西耶克、里耶卡、斯普利特和萨格勒布)的所有最后一年级学生都被邀请参加2015年和2019年的活动。准备得分分为“专题准备得分”和“全球准备得分”。主题准备分数代表了医学院学生对每个主题做好充分准备的百分比。它们首先在医学院一级建立,然后在国家一级建立。全球准备分数分别为每个学生确定,然后在医学院和国家层面计算。结果:与2019年的结果相比,2015年该国的全球准备得分(代表学生感到准备充分的主题的平均比例)略高(62.7%对56.5%;P = 0.191)。克罗地亚学生报告称,在调查涵盖的27个主题中,2015年有25个主题的准备程度高于2019年。2015年和2019年,大多数学生报告需要更多抗生素使用方面的教育(78.0%对83.0%;P = 0.199)。结论:尽管各种卫生保健机构的抗菌药物管理活动越来越多,但即将开始自己开抗生素处方的医学生并没有做好充分的准备。抗菌药物管理项目的设计应纳入本科医学生教育,例如,作为一个特定的,必修课程或整合到其他课程,如临床药理学。
{"title":"Antimicrobial Prescribing Preparedness of Croatian Medical Students-Did It Change between 2015 and 2019?","authors":"Dora Palčevski,&nbsp;Andrej Belančić,&nbsp;Ivan Mikuličić,&nbsp;Eduard Oštarijaš,&nbsp;Robert Likić,&nbsp;Oliver Dyar,&nbsp;Vera Vlahović-Palčevski","doi":"10.3390/medicines10070039","DOIUrl":"https://doi.org/10.3390/medicines10070039","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobials are some of the most prescribed drugs by junior doctors, but studies suggest most medical graduates feel unprepared for their future prescribing tasks. The aim of the present study was to compare the self-reported preparedness to prudently prescribe antimicrobials of final-year medical students in Croatia in 2015 and 2019.</p><p><strong>Methods: </strong>The same self-reported web-based survey on the preparedness to prescribe antibiotics was used in both 2015 and 2019. All final-year students at all four medical schools in Croatia (Osijek, Rijeka, Split, and Zagreb) were invited to participate in both 2015 and 2019. Preparedness scores were divided into \"topic preparedness scores\" and \"global preparedness scores\". Topic preparedness scores represented the percentage of students at a medical school who felt sufficiently prepared for each topic. They were first established at a medical school level and then at the national level. Global preparedness scores were determined for each student separately and then calculated at the medical school and national levels.</p><p><strong>Results: </strong>The country's global preparedness score, representing the average proportion of topics in which students felt sufficiently prepared, was slightly higher in 2015 compared with the 2019 results (62.7% vs. 56.5%; <i>p</i> = 0.191). Croatian students reported higher preparedness in 2015 than in 2019 for 25 out of 27 topics included in the survey. The majority of students reported a need for more education on antibiotic use both in 2015 and 2019 (78.0% vs. 83.0%; <i>p</i> = 0.199).</p><p><strong>Conclusions: </strong>Despite increasing antimicrobial stewardship activities in various healthcare settings, medical students who are about to start prescribing antibiotics on their own do not feel sufficiently prepared to do so. Antimicrobial stewardship programs should be designed to incorporate undergraduate medical student education, for instance, as a specific, mandatory course or integrated into other courses, such as clinical pharmacology.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9884451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-Seeking Behavior Regarding Coughs in Urban Slums in Lagos, Nigeria. 尼日利亚拉各斯城市贫民窟的咳嗽求医行为。
Pub Date : 2023-06-26 DOI: 10.3390/medicines10070038
Victor Abiola Adepoju, Olanrewaju Oladimeji, Olusola Daniel Sokoya

Background: TB is a major cause of morbidity and mortality, with slum residents being disproportionately affected. This study aimed to assess health-seeking behavior among adult residents of slum communities presenting with coughs in Lagos, Nigeria.

Methods: A community-based, cross-sectional study was conducted across six urban slums in Nigeria as part of community outreaches to mark World TB Day. A structured, pretested questionnaire was used to capture relevant sociodemographic details and questions regarding symptoms of coughs and related symptoms as well as care-seeking behavior. Data were explored, analyzed, and presented using descriptive statistics.

Results: A total of 632 respondents participated in this study. The majority were 25-34 years old (24.7%), male (65.8%), Christian (55.7%), married (73.7%), with secondary education (37.8%), with 3-4 persons per household (41%) and with 1-2 persons per room (44.5%). In total, 26.6% had had a cough for two weeks or more and were considered as presumptive TB patients. Overall, 37.2% of respondents with a cough visited patent proprietary medicine vendors (PPMVs) as the first port of call. Good health-seeking behavior was exhibited by only 36.2% of respondents. In total, 38.9% delayed seeking care from a health facility (government or private) more than one month after the onset of symptoms. None of the factors included in the multivariate analysis showed a significant association with good health-seeking behavior (i.e., visiting government or private hospitals/clinics).

Conclusions: The poor health-seeking behavior, delay in seeking TB care and preference for PPMVs emphasizes the need for National tuberculosis programs (NTPs) to further engage these informal providers in TB prevention, diagnosis and treatment services in urban slum communities.

背景:结核病是发病和死亡的主要原因,贫民窟居民受到的影响尤为严重。本研究旨在评估尼日利亚拉各斯贫民窟社区成年居民因咳嗽而寻求健康的行为:作为纪念世界防治结核病日社区外展活动的一部分,我们在尼日利亚的六个城市贫民窟开展了一项基于社区的横断面研究。研究使用了一份结构化的、经过预先测试的调查问卷,以收集相关的社会人口详情和有关咳嗽症状及相关症状以及寻求护理行为的问题。我们采用描述性统计方法对数据进行了挖掘、分析和展示:共有 632 名受访者参与了此次研究。大多数受访者年龄在 25-34 岁之间(24.7%),男性(65.8%),基督徒(55.7%),已婚(73.7%),受过中等教育(37.8%),每个家庭有 3-4 人(41%),每个房间有 1-2 人(44.5%)。总共有 26.6% 的人咳嗽两周或两周以上,被视为推定肺结核患者。总体而言,37.2%的咳嗽受访者首先到中成药商贩处就诊。只有 36.2% 的受访者表现出良好的求医行为。总共有 38.9% 的受访者在出现症状超过一个月后才到医疗机构(政府或私人)就医。多变量分析中的所有因素均未显示出与良好的求医行为(即到政府或私立医院/诊所就医)有显著关联:不良的求医行为、延迟寻求结核病治疗以及偏好 PPMVs 强调了国家结核病防治计划(NTP)进一步让这些非正规医疗机构参与城市贫民窟社区结核病预防、诊断和治疗服务的必要性。
{"title":"Health-Seeking Behavior Regarding Coughs in Urban Slums in Lagos, Nigeria.","authors":"Victor Abiola Adepoju, Olanrewaju Oladimeji, Olusola Daniel Sokoya","doi":"10.3390/medicines10070038","DOIUrl":"10.3390/medicines10070038","url":null,"abstract":"<p><strong>Background: </strong>TB is a major cause of morbidity and mortality, with slum residents being disproportionately affected. This study aimed to assess health-seeking behavior among adult residents of slum communities presenting with coughs in Lagos, Nigeria.</p><p><strong>Methods: </strong>A community-based, cross-sectional study was conducted across six urban slums in Nigeria as part of community outreaches to mark World TB Day. A structured, pretested questionnaire was used to capture relevant sociodemographic details and questions regarding symptoms of coughs and related symptoms as well as care-seeking behavior. Data were explored, analyzed, and presented using descriptive statistics.</p><p><strong>Results: </strong>A total of 632 respondents participated in this study. The majority were 25-34 years old (24.7%), male (65.8%), Christian (55.7%), married (73.7%), with secondary education (37.8%), with 3-4 persons per household (41%) and with 1-2 persons per room (44.5%). In total, 26.6% had had a cough for two weeks or more and were considered as presumptive TB patients. Overall, 37.2% of respondents with a cough visited patent proprietary medicine vendors (PPMVs) as the first port of call. Good health-seeking behavior was exhibited by only 36.2% of respondents. In total, 38.9% delayed seeking care from a health facility (government or private) more than one month after the onset of symptoms. None of the factors included in the multivariate analysis showed a significant association with good health-seeking behavior (i.e., visiting government or private hospitals/clinics).</p><p><strong>Conclusions: </strong>The poor health-seeking behavior, delay in seeking TB care and preference for PPMVs emphasizes the need for National tuberculosis programs (NTPs) to further engage these informal providers in TB prevention, diagnosis and treatment services in urban slum communities.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9894473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rhinosinusitis Treatment with Cineole: Patient-Reported Quality of Life Improvements from a Non-Interventional, Pharmacy-Based Survey. 桉树脑治疗鼻窦炎:一项非介入性、基于药物的调查显示患者报告的生活质量改善。
Pub Date : 2023-06-19 DOI: 10.3390/medicines10060037
Nina Werkhäuser, Ursula Pieper-Fürst, Hacer Sahin, Antonia Claas, Ralph Mösges

Background: Rhinosinusitis is commonly treated with decongestants, analgesics, and local corticosteroids. Phytotherapeutics are also utilised for symptomatic relief, including cineole, the main component of eucalyptus oil.

Methods: The current non-interventional, anonymised survey investigated quality of life in participants with rhinosinusitis (with or without additional symptoms of bronchitis) via the German version of a validated quality of life questionnaire (RhinoQol). Overall, 310 subjects administered a cineole preparation (Sinolpan) and 40 subjects applying nasal decongestant were recruited in German pharmacies.

Results: Significant improvements in frequency (64.0%), bothersomeness (52.1%), and impact (53.9%) of rhinosinusitis symptoms were reported upon treatment with cineole over a mean treatment period of seven days (p < 0.001 each). The overall treatment efficacy of cineole was evaluated as good or very good by 90.0% of the participants, and the quality of life during work or leisure time improved upon treatment. Six (non-serious) possibly related side effects were reported in four participants who were administered cineole. The tolerability of the treatment was assessed as good or very good by 93.9% of the participants.

Conclusions: Cineole can be considered as a safe and well-tolerated rhinosinusitis treatment conferring a clear improvement in quality of life outcomes.

背景:鼻窦炎通常用减充血剂、镇痛药和局部皮质类固醇治疗。植物疗法也用于缓解症状,包括桉树油的主要成分桉树脑。方法:目前的非介入性匿名调查通过德国版的有效生活质量问卷(RhinoQol)调查了患有鼻窦炎(伴有或不伴有支气管炎的额外症状)的参与者的生活质量。总体而言,在德国药房招募了310名受试者使用桉树脑制剂(Sinolpan), 40名受试者使用鼻减充血剂。结果:在平均7天的治疗期内,桉树脑治疗鼻窦炎症状的频率(64.0%)、困扰(52.1%)和影响(53.9%)均有显著改善(p < 0.001)。90.0%的参与者评价桉树脑的总体治疗效果为良好或非常好,治疗后工作或休闲时间的生活质量得到改善。四名服用桉树脑的参与者报告了六种(非严重)可能相关的副作用。93.9%的参与者评价该治疗的耐受性为良好或非常好。结论:桉树脑可以被认为是一种安全且耐受性良好的鼻窦炎治疗方法,可以明显改善患者的生活质量。
{"title":"Rhinosinusitis Treatment with Cineole: Patient-Reported Quality of Life Improvements from a Non-Interventional, Pharmacy-Based Survey.","authors":"Nina Werkhäuser,&nbsp;Ursula Pieper-Fürst,&nbsp;Hacer Sahin,&nbsp;Antonia Claas,&nbsp;Ralph Mösges","doi":"10.3390/medicines10060037","DOIUrl":"https://doi.org/10.3390/medicines10060037","url":null,"abstract":"<p><strong>Background: </strong>Rhinosinusitis is commonly treated with decongestants, analgesics, and local corticosteroids. Phytotherapeutics are also utilised for symptomatic relief, including cineole, the main component of eucalyptus oil.</p><p><strong>Methods: </strong>The current non-interventional, anonymised survey investigated quality of life in participants with rhinosinusitis (with or without additional symptoms of bronchitis) via the German version of a validated quality of life questionnaire (RhinoQol). Overall, 310 subjects administered a cineole preparation (Sinolpan) and 40 subjects applying nasal decongestant were recruited in German pharmacies.</p><p><strong>Results: </strong>Significant improvements in frequency (64.0%), bothersomeness (52.1%), and impact (53.9%) of rhinosinusitis symptoms were reported upon treatment with cineole over a mean treatment period of seven days (<i>p</i> < 0.001 each). The overall treatment efficacy of cineole was evaluated as good or very good by 90.0% of the participants, and the quality of life during work or leisure time improved upon treatment. Six (non-serious) possibly related side effects were reported in four participants who were administered cineole. The tolerability of the treatment was assessed as good or very good by 93.9% of the participants.</p><p><strong>Conclusions: </strong>Cineole can be considered as a safe and well-tolerated rhinosinusitis treatment conferring a clear improvement in quality of life outcomes.</p>","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"10 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10096468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicines (Basel, Switzerland)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1